Physician profile
Todd E Bullock
NPI 1104822360
$1,335.36
in general payments reported to CMS, 2019-2025
26 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $183 · 2023: $221 · 2024: $154 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $175.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $129.91 | 2021-2022 | |
| Lilly USA, LLC | $106.91 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $106.57 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $91.26 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $80.41 | 2022-2025 | |
| Amgen INC. | $59.70 | 2021-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.09 | 2022 | |
| Amarin Pharma, INC. | $36.77 | 2021 | |
| Dexcom, INC. | $34.40 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.69 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $31.07 | 2021-2022 | |
| Gilead Sciences, INC. | $24.34 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2024 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.01 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.14 | 2021 | |
| Medtronic, INC. | $13.31 | 2024 | Endurant Iis |
| Phathom Pharmaceuticals, INC. | $13.13 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $12.97 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.83 | 2023 | Eliquis |
| Mylan Specialty L.P. | $12.39 | 2022 | |
| Eisai INC. | $11.90 | 2021 | |
| Metacel Pharmaceuticals LLC | $7.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bullock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.